Actively Recruiting
Assessment of No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track
Led by Kafrelsheikh University · Updated on 2025-05-13
60
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to evaluate the no-reflow phenomenon in patients who have experienced ST-segment-elevation myocardial infarction (STEMI), a condition caused by blockage of a coronary artery due to plaque rupture or erosion. The study focuses on the use of intracoronary glycoprotein IIb/IIIa inhibitors, specifically tirofiban, after reopening the artery to improve blood flow in these patients. No-reflow is a common cause of complications after STEMI, and the study investigates strategies to address it. Participants will be randomly assigned to receive either intracoronary tirofiban (25 mg/kg) or a control treatment of intracoronary saline 0.9% solution. Both treatments are delivered directly into the coronary artery after the blocked artery is opened during the primary percutaneous coronary intervention (PCI). The study uses a double-blind design to compare the effects of tirofiban versus saline on blood flow and heart event outcomes. Throughout the study, researchers will monitor blood flow within 15 minutes after treatment to assess the primary outcome. They will also track the incidence of major adverse cardiac events for up to 30 days following treatment. Participants will undergo regular evaluations to measure heart function and safety. The entire participation period includes treatment and follow-up to determine treatment impact on blood flow and cardiac events.
CONDITIONS
Brief Title
No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 63; 18 years old
- Both sexes
- Patients with ST-segment-elevation myocardial infarction (STEMI), defined as chest pain over 30 minutes with specific ECG changes or new left bundle branch block
You will not qualify if you...
- Treatment with thrombolytic drugs in the previous 24 hours
- Known malignancy
- Thrombocytopenia
- End-stage liver disease
- Cardiogenic shock
- Renal failure with glomerular filtration <30 ml/min
- Contraindication for the use of tirofiban
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 15 minutes
Participants receive intracoronary tirofiban or saline 0.9% solution after opening of the coronary artery as part of their treatment for STEMI.
1 treatment visit (in-person)
Duration - Up to 30 days
Participants are monitored for major adverse cardiac events following treatment.
Approximately 1 follow-up visit
Trial Site Locations
Total: 1 location
1
Kafrelsheikh University
Kafr ash Shaykh, Kafrelsheikh, Egypt, 33516
Actively Recruiting
Research Team
M
Mohammed A Hammad, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here